Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versu
- PDF / 1,011,691 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 20 Downloads / 216 Views
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft‑versus‑host disease Dina Ljubas Kelecic1 · Antonela Lelas2 · Irena Karas1 · Lana Desnica3 · Tamara Vukic4 · Ivan Sabol5 · Darija Vranesic Bender1 · Ranka Serventi Seiwerth3 · Zinaida Peric2,3 · Nadira Durakovic2,3 · Dubravka Vitali Cepo6 · Radovan Vrhovac2,3 · Damir Nemet2,3 · Steven Pavletic7 · Drazen Pulanic2,3 · Zeljko Krznaric1,2,8 Received: 2 March 2020 / Accepted: 30 May 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose This study investigated the frequency and characteristics of sarcopenia among patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a specific focus on the chronic graft-versus-host disease (cGVHD) population and its association with malnutrition, vitamin D and clinical characteristics. Methods We assessed sarcopenia, vitamin D levels, and nutritional status in 73 patients who underwent allo-HSCT, of which 45 were diagnosed with cGVHD. Sarcopenia was diagnosed according to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria. Results Sarcopenia was diagnosed in 19.2% of patients after allo-HSCT with statistically no significant difference between cGVHD and non-cGVHD patients. The risk factor for sarcopenia was the male gender. Sarcopenia in allo-HSCT patients correlated strongly with malnutrition and with current corticosteroid treatment (p
Data Loading...
